[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vericel Corporation (VCEL)

Vericel Corporation (VCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,047,827
  • Shares Outstanding, K 51,068
  • Annual Sales, $ 276,260 K
  • Annual Income, $ 16,520 K
  • EBIT $ 16 M
  • EBITDA $ 27 M
  • 60-Month Beta 1.12
  • Price/Sales 7.23
  • Price/Cash Flow 72.19
  • Price/Book 5.73

Options Overview Details

View History
  • Implied Volatility 53.37% (-1.38%)
  • Historical Volatility 39.00%
  • IV Percentile 4%
  • IV Rank 11.05%
  • IV High 95.07% on 02/09/26
  • IV Low 48.19% on 10/20/25
  • Expected Move (DTE 25) 1.70 (4.24%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 63
  • Volume Avg (30-Day) 132
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 1,115
  • Open Int (30-Day) 805
  • Expected Range 38.40 to 41.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.04
  • Number of Estimates 1
  • High Estimate $-0.04
  • Low Estimate $-0.04
  • Prior Year $-0.01
  • Growth Rate Est. (year over year) -300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.01 +25.27%
on 06/02/26
40.60 -1.23%
on 06/18/26
+5.23 (+15.00%)
since 05/18/26
3-Month
28.95 +38.51%
on 03/27/26
40.85 -1.84%
on 05/07/26
+7.80 (+24.15%)
since 03/18/26
52-Week
28.95 +38.51%
on 03/27/26
43.57 -7.96%
on 06/30/25
-1.68 (-4.02%)
since 06/18/25

Most Recent Stories

More News
Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026

BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 40.10 (+2.48%)
Vericel Q1 Earnings Call Highlights

Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected...

VCEL : 40.10 (+2.48%)
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1...

VCEL : 40.10 (+2.48%)
Vericel's Revenue Momentum Looks Solid but the Path to Profit Keeps Getting Pushed Out

Barchart Research What to Expect from VCEL Earnings VCEL Generated May 6, 2026 Current Price $36.78 EPS Estimate $$-0.14 Consensus Rating Strong Buy Average Move 5.40% Vericel's Revenue Momentum Looks...

VCEL : 40.10 (+2.48%)
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026

CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 40.10 (+2.48%)
Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year...

VCEL : 40.10 (+2.48%)
Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility

Company Achieves Significant Regulatory and Operational Milestone Substantially Increases Manufacturing Capacity to Support Long-Term Growth Enables Potential MACI Commercialization Outside of...

VCEL : 40.10 (+2.48%)
Vericel to Present at Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 40.10 (+2.48%)
Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results

Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record...

VCEL : 40.10 (+2.48%)
Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026

CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 40.10 (+2.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the...

See More

Key Turning Points

3rd Resistance Point 42.44
2nd Resistance Point 41.52
1st Resistance Point 40.81
Last Price 40.10
1st Support Level 39.18
2nd Support Level 38.26
3rd Support Level 37.55

See More

52-Week High 43.57
Last Price 40.10
Fibonacci 61.8% 37.99
Fibonacci 50% 36.26
Fibonacci 38.2% 34.53
52-Week Low 28.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.